The partnership focuses on testing wearable neurostimulation to prevent and treat acute stress reaction in the military. 

Spark Biomedical Inc., a U.S. leader in wearable neurostimulation solutions, is proud to announce the launch of telehealth services for their recently FDA-cleared product, Sparrow Ascent.

This FDA-cleared wearable neuromodulation system offers game-changing access for patients to start the road to recovery without interruptions to daily living

Collaborative study awarded to the University of Texas Medical Branch, Medical University of South Carolina, and Spark Biomedical

Spark Biomedical creates a subsidiary, Five Liters, to focus the initiative while taking advantage of the company’s experience in turning patents into FDA-approved products.

The jointly run pilot clinical study is the first step in pioneering closed-loop opioid withdrawal detection and treatment 

The Medical University of South Carolina and UT Southwestern Medical Center join Spark Biomedical in Phase II clinical trial.

Spark Biomedical, Inc, the Hazelden Betty Ford Foundation, and Gaudenzia, Inc. Unite in Effort to Help Patients Reduce Relapse Risks and Sustain Recovery From Opioid Use Disorder

Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services (HHS), Eric D. Hargan, and his consulting firm, The Hargan Group, to help make novel withdrawal relief treatment more accessible and affordable for patients

First residential treatment center in the nation to offer The Sparrow™ Therapy System.